Memantine Genepharm (Memantine Hydrochloride)

Memantine acts as a non‑competitive antagonist of the NMDA receptor. By blocking excessive activation of this receptor, it reduces calcium influx and limits glutamate‑mediated excitotoxic damage to neurons, a process that contributes to the progression of Alzheimer’s disease.

The dosage of Memantine Genepharm is determined by the prescribing clinician based on the patient’s condition, age, renal function, and other factors. The prescriber will set the appropriate dose and titration schedule according to current clinical guidelines.

Safety data for memantine in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare professional.

To place an order, submit an enquiry on the Memantine Genepharm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA‑receptor antagonist class, whereas many other Alzheimer’s drugs are cholinesterase inhibitors (e.g., donepezil, rivastigmine). Memantine targets excitotoxic pathways, while cholinesterase inhibitors enhance acetylcholine signaling. In practice, memantine is often used alone in moderate‑severe disease or combined with a cholinesterase inhibitor for broader symptom control.

Store Memantine Genepharm at room temperature, below 25 °C. Keep the tablets in the original blister pack or container, protect them from moisture, heat and direct sunlight, and keep out of reach of children.

Memantine Genepharm is taken orally, usually with water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include seizures, severe allergic reactions such as anaphylaxis, and life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any signs of these reactions.

Memantine Genepharm is contraindicated in individuals with known hypersensitivity to memantine or any of its excipients. It should also be avoided in patients with severe renal impairment unless dose adjustments are made, and in those with a history of uncontrolled seizures without appropriate monitoring.